- Home
- ANVS vs JSPR Comparison
ANVS vs JSPR Comparison
Compare ANVS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- JSPR
- Stock Information
- Founded
- ANVS 2008
- JSPR 2018
- Country
- ANVS United States
- JSPR United States
- Employees
- ANVS N/A
- JSPR N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANVS Health Care
- JSPR Health Care
- Exchange
- ANVS Nasdaq
- JSPR Nasdaq
- Market Cap
- ANVS 55.5M
- JSPR 47.6M
- IPO Year
- ANVS 2020
- JSPR N/A
- Fundamental
- Price
- ANVS $2.48
- JSPR $2.43
- Analyst Decision
- ANVS Strong Buy
- JSPR Buy
- Analyst Count
- ANVS 4
- JSPR 12
- Target Price
- ANVS $17.33
- JSPR $30.78
- AVG Volume (30 Days)
- ANVS 210.1K
- JSPR 154.4K
- Earning Date
- ANVS 11-07-2025
- JSPR 11-06-2025
- Dividend Yield
- ANVS N/A
- JSPR N/A
- EPS Growth
- ANVS N/A
- JSPR N/A
- EPS
- ANVS N/A
- JSPR N/A
- Revenue
- ANVS N/A
- JSPR N/A
- Revenue This Year
- ANVS N/A
- JSPR N/A
- Revenue Next Year
- ANVS N/A
- JSPR N/A
- P/E Ratio
- ANVS N/A
- JSPR N/A
- Revenue Growth
- ANVS N/A
- JSPR N/A
- 52 Week Low
- ANVS $1.11
- JSPR $2.27
- 52 Week High
- ANVS $10.54
- JSPR $26.05
- Technical
- Relative Strength Index (RSI)
- ANVS 52.16
- JSPR 28.63
- Support Level
- ANVS $2.26
- JSPR $2.50
- Resistance Level
- ANVS $2.51
- JSPR $2.87
- Average True Range (ATR)
- ANVS 0.12
- JSPR 0.12
- MACD
- ANVS 0.02
- JSPR -0.00
- Stochastic Oscillator
- ANVS 87.10
- JSPR 0.00
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.